| __timestamp | Gilead Sciences, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 3788000000 | 520990000000 |
| Thursday, January 1, 2015 | 4006000000 | 535405000000 |
| Friday, January 1, 2016 | 4261000000 | 558755000000 |
| Sunday, January 1, 2017 | 4371000000 | 495921000000 |
| Monday, January 1, 2018 | 4853000000 | 659690000000 |
| Tuesday, January 1, 2019 | 4675000000 | 1089764000000 |
| Wednesday, January 1, 2020 | 4572000000 | 994308000000 |
| Friday, January 1, 2021 | 6601000000 | 1106846000000 |
| Saturday, January 1, 2022 | 5657000000 | 1244072000000 |
| Sunday, January 1, 2023 | 6498000000 | 1431505000000 |
| Monday, January 1, 2024 | 28675800000 | 1431505000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited from 2014 to 2023. Over this period, Gilead's cost of revenue has shown a steady increase, peaking in 2021 with a 74% rise from 2014. Meanwhile, Takeda's expenses have surged dramatically, with a 175% increase, reflecting its aggressive expansion and acquisition strategies.
Notably, Takeda's cost of revenue in 2023 is approximately 220 times that of Gilead, highlighting its vast scale. However, Gilead's consistent growth underscores its efficient cost management. Missing data for Gilead in 2024 suggests a need for further updates. This comparative insight offers a window into the strategic financial maneuvers of these pharmaceutical giants.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Gilead Sciences, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Gilead Sciences, Inc.
Gilead Sciences, Inc. or Takeda Pharmaceutical Company Limited: Who Invests More in Innovation?
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Telix Pharmaceuticals Limited
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Ionis Pharmaceuticals, Inc.
Gilead Sciences, Inc. vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs HUTCHMED (China) Limited
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Mesoblast Limited
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited
Analyzing Cost of Revenue: Takeda Pharmaceutical Company Limited and Cytokinetics, Incorporated
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Agios Pharmaceuticals, Inc.